Roche has secured CE mark approval for its immunohistochemistry (IHC) companion diagnostic test, VENTANA FOLR1 (FOLR1-2.1) ...

Swiss drug major Roche Group (RHHBY) announced Monday that it has received CE Mark for its VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, ...

The immunohistochemistry test detects the folate receptor 1 protein, which is over-expressed in most ovarian cancers.

Presented at the Clinical Trials in Alzheimer’s Disease congress, being held in Madrid, Spain, Roche’s diagnostics unit showed that a negative result from one test—its Elecsys amyloid plasma ...

Roche Holdings said it received Food and Drug Administration approval for its companion diagnostic of gastric and gastroesophageal junction cancer. The diagnostic, called the Ventana CLDN18 (43 ...

The alliance is with Roche Tissue Diagnostics (RTD), a unit of the Swiss pharma group that is concerned with the development of tissue-based tools to improve the diagnosis of cancer and grew out ...

Healthcare solutions provider Qure.ai has entered into a collaboration with Roche Diagnostics Asia Pacific’s Startup Creasphere (APAC) initiative to work on AI-driven medical imaging technologies.

U.S.-booked air volume for Roche was unchanged in 2023 at $76 million, and the pharmaceuticals and diagnostics company could post the same figure again for 2024. Roche does not anticipate returning to ...

Roche announced that the VENTANA CLDN18 (43-14A) RxDx Assay is the first immunohistochemistry (IHC) companion diagnostic test to receive CE Mark approval for determining CLDN18 protein expression in ...